Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.66 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72955 | 0.85 | CDK2 (0.50) | DYRK1AMAP3K14PKMCDK2CDK4 | |
| SCHEMBL182990 | 0.82 | DYRK1A (0.66) | DYRK1APKMCDK2IRAK4MAPK10 | |
| SCHEMBL26363435 | 0.80 | PKM (0.62) | DYRK1APKMIRAK4FLT3 | |
| SCHEMBL29883730 | 0.79 | MAP3K14 (0.66) | DYRK1AMAP3K14CDK2IGF1RMAPK9 | |
| SCHEMBL3557515 | 0.78 | DYRK1A (0.65) | DYRK1APKMCDK2IRAK4MAPK10 | |
| SCHEMBL1614011 | 0.77 | MAP3K14 (1.00) | DYRK1AMAP3K14CDK2CDK4FLT3 | |
| SCHEMBL17943211 | 0.76 | CDK2 (0.77) | DYRK1APKMCDK2CDK4IRAK4 | |
| SCHEMBL3548686 | 0.76 | DYRK1A (0.62) | DYRK1APKMCDK2CDK4IRAK4 | |
| SCHEMBL10238506 | 0.76 | PKM (0.61) | DYRK1APKMCDK2IRAK4IGF1R | |
| SCHEMBL29868755 | 0.76 | PKM (0.54) | DYRK1APKMCDK2IRAK4MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100415744-C | 2-arylamino-pyrimidines for the treatment of GSK3-related disorders | ASTRAZENECA AB (SE) | 2008-09-03 | — | — | CN | disclosed |
| US-7345050-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-03-18 | — | — | US | disclosed |
| CN-1294131-C | Pyrimidine compound | ASTRAZENECA AB (SE) | 2007-01-10 | — | — | CN | disclosed |
| CN-1823064-A | 2-arylamino-pyrimidines for the treatment of GSK 3-related disorders | ASTRAZENECA AB (SE) | 2006-08-23 | — | — | CN | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| CN-1537112-A | Pyrimidine compound | — | 2004-10-13 | — | — | CN | disclosed |
| US-20040077642-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| EP-1373266-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002065979-A2 | (DIAZOLO-PYRIDINYL)-PYRIMIDINES FOR USE IN TREATMENT OF CNS DISORDERS AND DIABETES | ASTRAZENECA AB (SE) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077642-A1 | Pyrimidine compounds | TYMP, DPYD, TYMS | DYRK1A 3773/4885MAP3K14 2655/4885PKM 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.